RadioMedix expands thorium-228 supply for 212Pb

Targeted radiopharmaceuticals specialist RadioMedix, Inc. announced a five-year supply agreement with Van Overeem Nuclear B.V. (The Netherlands) for Thorium-228 (²²⁸Th). The deal secures a critical upstream isotope source, reinforcing RadioMedix’s 212Pb (Lead-212) generator platform and supporting its development of Targeted Alpha Therapy (TAT) candidates.

“Securing a reliable supply of ²²⁸Th is a fundamental step in building the infrastructure required for ²¹²Pb production,” said Ebrahim S. Delpassand, M.D., CEO of RadioMedix. “This agreement strengthens our ability to meet future clinical and manufacturing demand.”

Under the agreement, Van Overeem Nuclear will supply ²²⁸Th as the precursor for 212Pb production. The isotope will be used in RadioMedix’s RAHA-100 bench-top generator, which produces 212Pb for preclinical and clinical development of alpha-emitting radiopharmaceuticals.

“212Pb is an important radionuclide for targeted alpha therapies in oncology,” said Philippe van Overeem, CEO of Van Overeem Nuclear. “We are supplying RadioMedix with this isotope to support clinical development.”

Market positioning

Large players in the targeted radiopharmaceutical sector such as Novartis AG have commercialised therapies like Pluvicto (177Lu-PSMA-617), leveraging established global infrastructure, regulatory experience, and substantial R&D budgets. Smaller firms, including ITM Isotope Technologies Munich, are integrated producers that develop, manufacture, and supply both radioisotopes and radiopharmaceuticals from their own facilities.

RadioMedix is a smaller specialist that focuses on 212Pb-based therapies. Its RAHA-100 generator allows internal production of 212Pb, providing direct control over isotope availability for clinical trials. Compared with global pharma, RadioMedix has a narrower pipeline and less commercial reach, but its approach provides flexibility in early-stage development and niche indications. Compared with integrated competitors such as ITM, RadioMedix differentiates through its multiple upstream isotope sources and proprietary generator technology, supporting scalable 212Pb production—a key factor in expanding alpha-emitter therapy availability.

This positions RadioMedix as a mid-sized, development-focused player in the alpha-emitter radiopharmaceutical market, with capabilities primarily in early and mid-stage clinical development rather than global commercialisation.